Oxurion Announces Two Presentations at The Macula Society 45th Annual Meeting
June 13, 2022 13:00 ET
|
Oxurion NV
Leuven, BELGIUM, Boston, MA, US – JUNE 13, 2022 – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next generation standard of care ophthalmic therapies, with clinical...
Oxurion Announces Preclinical Presentation on THR-149 at KININ2022
June 07, 2022 13:00 ET
|
Oxurion NV
Leuven, BELGIUM, Boston, MA, US – JUNE 7, 2022 – Oxurion NV (Euronext Brussels: OXUR), a clinical stage biopharmaceutical company developing next generation standard of care ophthalmic therapies in...
Oxurion Announces Two Upcoming Presentations at The Macula Society 45th Annual Meeting
June 03, 2022 02:00 ET
|
Oxurion NV
Leuven, BELGIUM, Boston, MA, US – JUNE 3, 2022 – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next generation standard of care ophthalmic therapies, with clinical stage...
Oxurion to Participate in Upcoming Investor Conferences
June 01, 2022 13:15 ET
|
Oxurion NV
Leuven, BELGIUM, Boston, MA, US – June 1, 2022 – Oxurion NV (Euronext Brussels: OXUR) a biopharmaceutical company developing next generation standard of care ophthalmic therapies, with clinical stage...
Informatie met betrekking tot het Totaal Aantal Stemrechten (Noemer) volgend op NEGMA Conversie-Notificatie
May 31, 2022 13:00 ET
|
Oxurion NV
Negma Group heeft 200 converteerbare obligaties in Oxurion geconverteerd resulterende in een kapitaalverhoging van EUR 500.000. Deze conversie vormt deel van Negma Group’s EUR 30 miljoen...
Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from NEGMA
May 31, 2022 13:00 ET
|
Oxurion NV
Negma Group has converted 200 convertible bonds in Oxurion resulting in a EUR 500,000 capital increase. This is part of Negma Group’s EUR 30 million Capital Commitment1 that will allow Oxurion to...
Oxurion Kondigt Resultaten aan van de Buitengewone Aandeelhoudersvergadering gehouden op 24 mei 2022
May 25, 2022 13:00 ET
|
Oxurion NV
Leuven, België, Boston, MA, VS – 25 mei 2022 – 19.00u CET – Oxurion NV (Euronext Brussels: OXUR) (de “Vennootschap” of “Oxurion”), een biofarmaceutisch bedrijf dat oogheelkundige...
Oxurion Announces Results of the Extraordinary Shareholders’ Meeting held on 24 May 2022
May 25, 2022 13:00 ET
|
Oxurion NV
Leuven, Belgium, Boston, MA, US – May 25, 2022 – 07.00 PM CET – Oxurion NV (Euronext Brussels: OXUR) (the “Company” or “Oxurion”), a biopharmaceutical company developing next generation standard...
Oxurion Announces Upcoming Preclinical Presentation on THR-149 at KININ2022
May 24, 2022 13:00 ET
|
Oxurion NV
Leuven, BELGIUM, Boston, MA, US – MAY 24, 2022 – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next generation standard of care ophthalmic therapies, with clinical stage...
Oxurion Announces Top-Line Results from Part A of Phase 2 INTEGRAL Trial Evaluating THR-687 for Treatment of Diabetic Macular Edema (DME)
May 09, 2022 02:30 ET
|
Oxurion NV
Trial did not demonstrate efficacy on the key clinical endpoints Oxurion to focus on its Phase 2 development program for THR-149 Leuven, BELGIUM, Boston, MA, US – MAY 9, 2022 – 8:30 AM CET –...